Immix Biopharma reported complete remissions in 89% of patients in a clinical update for its CAR-T therapy in AL amyloidosis, a rare autoimmune disorder where misfolded proteins accumulate in organs including the heart and kidneys. The headline outcome adds to the momentum for CAR-T approaches in protein-aggregation diseases, where durable clearance of target cells and depth of response drive long-term organ protection. The data also raise expectations for ongoing or planned expansion cohorts depending on safety and manufacturing performance. For the CAR-T field, the update is another data point supporting a move beyond lymphoma into immune-mediated hematologic targets where patient selection and conditioning strategies can materially affect outcomes.